SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for the treatment of central nervous system (CNS) disorders. Under the terms of the agreement, SandboxAQ received an upfront payment and will be eligible to receive additional preclinical, development, reg ...

SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for the treatment of central nervous system (CNS) disorders. Under the terms of the agreement, SandboxAQ received an upfront payment and will be eligible to receive additional preclinical, development, reg ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42914 FORM 10-Q (Mark One) MapLight Therapeutics, Inc. (Exact Name of Registrant as Specified in its Chart ...

Exhibit 99.1 MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress SAN FRANCISCO and BOSTON, Dec. 4, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter of 2025 and highlighted recent progress and upcoming milestones. "2025 was a year of exceptional ...

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the second half of 2027Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ...

Corporate Presentation December 4, 2025 Innovation-Driven Company Globally Recognized Scientific Founders Established in 2018 to >100 Employees Broad & Diversified Product Pipeline Safe Harbor and Forward-Looking Statements This presentation and any accompanying oral commentary have been prepared by MapLight Therapeutics, Inc. ("MapLight", "we," "us," "our," the "Company", or similar terms) for informational purposes only and not for any other purpose. This presentation contains trademarks, service marks, t ...

Core Points - MapLight Therapeutics, Inc. has successfully closed its initial public offering (IPO) of 16,962,500 shares at a price of $17.00 per share, including the full exercise of underwriters' option for an additional 2,212,500 shares [1][3] - The company also completed a concurrent private placement of 476,707 shares at the IPO price to affiliates of Goldman Sachs, which was not registered under the Securities Act [2][3] - The total gross proceeds from both the IPO and private placement amounted to $296.3 million before deducting underwriting discounts and expenses [3] Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on treating patients with central nervous system disorders [6] - The company was founded by leaders in psychiatry and neuroscience to develop circuit-specific pharmacotherapies [6] - Its lead product candidate, ML-007C-MA, is currently in Phase 2 clinical trials for schizophrenia and Alzheimer's disease psychosis [6]

Core Viewpoint - Maplight Therapeutics (MPLT.US) has successfully launched on the US stock market, with shares rising over 15.8% to $19.7, following an IPO price of $17, indicating strong market interest in its innovative approach to treating central nervous system disorders [1] Company Overview - Maplight Therapeutics was founded by renowned leaders in psychiatry and neuroscience, focusing on addressing the lack of targeted drug therapies for specific neural circuits in patients [1] - The company has developed a platform capable of identifying neural circuits causally related to diseases, allowing for targeted therapeutic modulation [1] Product Pipeline - Maplight has created a range of candidate products aimed at treating some of the most challenging central nervous system diseases, including schizophrenia, Alzheimer's disease, and autism spectrum disorders [1]

Core Insights - Maplight Therapeutics (MPLT.US) has successfully launched on the US stock market, with shares rising over 15.8% to $19.7, after an IPO price of $17 [1] Company Overview - Maplight Therapeutics was founded by renowned leaders in psychiatry and neuroscience, focusing on addressing the lack of targeted drug therapies for specific neural circuits [1] - The company claims its platform can identify neural circuits causally related to diseases and provide therapeutic modulation for these circuits [1] Product Development - Maplight has developed a range of candidate products aimed at treating some of the most challenging central nervous system diseases, including schizophrenia, Alzheimer's disease, and autism spectrum disorders [1]

Core Insights - MapLight Therapeutics shares opened 11.8% above their offer price during their Nasdaq debut, indicating strong market interest and demand for the company's stock [1] - The initial valuation of MapLight Therapeutics reached $787 million, reflecting investor confidence in the drug developer's potential [1] Company Summary - MapLight Therapeutics is a drug developer that has recently gone public, showcasing its growth potential through a successful Nasdaq debut [1] - The company's stock performance on its first day suggests a positive reception from investors, which may indicate future opportunities for capital raising and expansion [1]